Next Week's Earnings Focus on Netflix, 3M, and More
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1d ago
0mins
Source: CNBC
- Earnings Week Outlook: Next week will feature earnings reports from Netflix, 3M, and D.R. Horton, with Cramer noting that despite disappointing results from homebuilders, he is starting to see 'green shoots' in the housing market, indicating potential recovery signs.
- 3M Surprises: Cramer highlights that 3M has been quietly surprising investors this year, and he expects its earnings report to continue delivering positive surprises, reflecting the company's success in diversifying its business.
- Johnson & Johnson's Strategic Shift: Cramer praises Johnson & Johnson's move towards becoming primarily a pharmaceutical company, suggesting that while it faces lawsuits related to talc products, these issues have limited impact on its stock price, demonstrating resilience in the market.
- Inflation Data Focus: The PCE price index will be released on Thursday, with Cramer anticipating a 'restrained set of numbers,' which could influence market expectations regarding inflation and subsequently affect investor decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 207.26 USD with a low forecast of 176.00 USD and a high forecast of 230.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 219.570
Low
176.00
Averages
207.26
High
230.00
Current: 219.570
Low
176.00
Averages
207.26
High
230.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
